Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results

Omthera Pharmaceuticals, Inc. (OMTH), an emerging specialty pharmaceutical company, today announced its financial results for the first quarter of 2013.

Omthera Pharmaceuticals also announced today that it had entered into a definitive merger agreement with AstraZeneca pursuant to which AstraZeneca will acquire Omthera for $12.70 per share, or approximately $323 million. In addition to the cash payment, each Omthera stockholder will receive one Contingent Value Right (CVR) of up to approximately $4.70 for each share they own, equating to $120 million, if specified milestones related to Epanova are achieved, or if a milestone related to global net sales is achieved. This will bring the total potential acquisition value to $443 million.

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion

Nordion Enters into Agreement to Divest Targeted Therapies Business to BTG plc

Nordion Inc. (NDN.TO) (NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced that it has entered into an agreement to divest its Targeted Therapies business to BTG plc (BTG.L) (“BTG”), an international specialist healthcare company based in London, United Kingdom, for a cash purchase price of US$200 million. Net of cash taxes and transaction costs, Nordion expects to realize approximately US$185 million on closing. The transaction is anticipated to be completed by the end of June 2013.

Nordion manufactures and commercializes TheraSphere®, a targeted liver cancer therapy, the sole product in its Targeted Therapies business. Under the terms of the transaction agreements, BTG is expected to acquire TheraSphere and Nordion has agreed to continue manufacturing TheraSphere under a Manufacturing and Support Agreement with a contract term of three years, plus a two-year extension at BTG’s option. Approximately 40 Nordion employees are expected to join BTG following the completion of this transaction, which is subject to customary closing conditions and approval by BTG shareholders.

NPS Pharmaceuticals Prices Public Offering of Common Stock

NPS Pharmaceuticals, Inc. (NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being sold by NPS. The gross proceeds to NPS from this offering are expected to be approximately $87.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by NPS. The offering is expected to close on or about May 24, 2013, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Leerink Swann LLC are acting as lead co-managers for the offering and Oppenheimer & Co. Inc. and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.